These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 4368383)

  • 1. Adriamycin in advanced bronchogenic carcinoma.
    Cortes EP; Takita H; Holland JF
    Cancer; 1974 Sep; 34(3):518-25. PubMed ID: 4368383
    [No Abstract]   [Full Text] [Related]  

  • 2. MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.
    Chahinian AP; Mandel EM; Holland JF; Jaffrey IS; Teirstein AS
    Cancer; 1979 May; 43(5):1590-7. PubMed ID: 221093
    [No Abstract]   [Full Text] [Related]  

  • 3. CCNU-adriamycin therapy in bronchogenic carcinoma.
    Trowbridge RC; Kennedy BJ; Vosika GJ
    Cancer; 1978 May; 41(5):1704-9. PubMed ID: 206337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of adriamycin, CCNU and hydroxyurea in the treatment of disseminated bronchogenic carcinoma.
    Alberto P; Barrelet L; Chapuis B; Garcia B
    Eur J Cancer (1965); 1975 Nov; 11(11):795-9. PubMed ID: 767111
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of a clinical trial with intermittent doses of adriamycin in lung cancer.
    Kenis Y; Michel J; Rimoldi R; Lévy P; Israël L
    Eur J Cancer (1965); 1972 Oct; 8(5):485-9. PubMed ID: 4346865
    [No Abstract]   [Full Text] [Related]  

  • 6. Ftorafur, adriamycin and mitomycin C (FAM II) for extensive bronchogenic adenocarcinoma and large cell carcinoma.
    Salvati F; Cruciani AR; De Marinis A; Nunziati F; Portalone L
    Jpn J Clin Oncol; 1984 Mar; 14(1):3-6. PubMed ID: 6323790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
    Stolinsky DC; Bull FE; Pajak TF; Bateman JR
    Oncology; 1975; 31(5-6):288-92. PubMed ID: 174040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.
    Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK; Coles DT
    Cancer Treat Rep; 1981; 65(11-12):1099-1101. PubMed ID: 6271397
    [No Abstract]   [Full Text] [Related]  

  • 9. VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary.
    Samson MK; Baker LH; Talley RW; Fraile RJ
    Eur J Cancer (1965); 1978 Dec; 14(12):1395-9. PubMed ID: 216556
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
    Haas CD; Baker L; Thigpen T
    Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cis-dichlorodiammineplatinum, adriamycin and cyclophosphamide versus cis-dichlorodiammineplatinum, adriamycin, cyclophosphamide and CCNU in non-small cell carcinoma of the lung].
    Sanz Ortiz J; Saiz García F
    Med Clin (Barc); 1982 Nov 16-30; 79(9):403-6. PubMed ID: 6296560
    [No Abstract]   [Full Text] [Related]  

  • 12. Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine.
    Mintz U; Bitran JD; Cooksey JA; Desser RK; DeMeester TR; Golomb HM
    Cancer Treat Rep; 1978 Apr; 62(4):567-9. PubMed ID: 77725
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II evaluation of vindesine in non-small cell bronchogenic carcinoma.
    Hutcheon AW; Palmer JB; Pratt MA; Clark RA
    Cancer Treat Rep; 1983 Nov; 67(11):1041-2. PubMed ID: 6315231
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
    Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer.
    Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK
    Cancer Treat Rep; 1981; 65(5-6):517-9. PubMed ID: 7195306
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II trial of 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
    Joss RA; Obrecht JP; Alberto P; Siegenthaler P; VanHelvoirt A; Cavalli F
    Cancer Treat Rep; 1984 Mar; 68(3):563-4. PubMed ID: 6322990
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination chemotherapy with adriamycin and cyclophosphamide (with or without radiation therapy) for carcinoma of the lung.
    Herman TS; Jones SE; McMahon LJ; Lloyd RE; Heusinkveld RS; Miller RC; Salmon SE
    Cancer Treat Rep; 1977 Aug; 61(5):875-9. PubMed ID: 196753
    [No Abstract]   [Full Text] [Related]  

  • 18. Adriamycin and Cytoxan in the treatment of inoperable lung cancer.
    Hoeltgen TM; MacIntyre JM; Perlia CP; Lagakos SW; Stolbach LL; Bennett JM
    Cancer; 1983 Jun; 51(11):2005-12. PubMed ID: 6301671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adriamycin and adriamycin--DNA in inoperable bronchogenic carcinoma. A randomized study with cyclophosphamide vinblastine.
    Bosly A; Prignot J; Ledent C; Sokal G; Trouet A
    Eur J Cancer (1965); 1978 Jun; 14(6):639-44. PubMed ID: 658087
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
    Cohen JL; Krant MJ; Shnider BI; Matias PI; Horton J; Baxter D
    Cancer Chemother Rep; 1971 Jun; 55(3):253-8. PubMed ID: 5115846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.